In Margaret A. Lloyd (ed.). Mayo Clinic Cardiology: Concise Textbook. Joseph G. Murphy. OUP USA. pp. 196–202. ISBN 978-0-19-991571-2. Blumenthal RS, Margolis S (2007). Heart Attack Prevention 2007. Johns Hopkins Health. ISBN 978-1-933087-47-4. Dwight J (16 June 2016). "Chest pain, breathlessness, fatigue". In Timothy Cox (ed.). Oxford Textbook of Medicine: Cardiovascular Disorders. Jeremy Dwight. Oxford University Press. pp. 39–47. ISBN 978-0-19-871702-7. Gaziano TA, Gaziano JM (15 September 2016). "Global Evolving Epidemiology, Natural History, and Treatment Trends of Myocardial Infarction". In Morrow DA (ed.). Myocardial Infarction: A Companion to Braunwalds Heart Disease. Elsevier. pp. 11–21. ISBN 978-0-323-35943-6. Morrow DA, Bohula EA (15 September 2016). "Heart Failure and Cardiogenic Shock After Myocardial Infarction". In Morrow DA (ed.). Myocardial Infarction: A Companion to Braunwalds Heart Disease. Elsevier. pp. 295–313. ISBN 978-0-323-35943-6. Morrow DA, Braunwald E (15 September 2016). "Classification and Diagnosis of Acute Coronary Syndromes". In Morrow DA (ed.). Myocardial Infarction: A Companion to Braunwalds Heart Disease. Elsevier. pp. 1–10. ISBN 978-0-323-35943-6. Morrow DA (15 September 2016). "Clinical Approach to Suspected Acute Myocardial Infarction". In Morrow DA (ed.). Myocardial Infarction: A Companion to Braunwalds Heart Disease. Elsevier. pp. 55–65. ISBN 978-0-323-35943-6. Further reading
External links

Myocardial infarction at Curlie
American Heart Associations Heart Attack web site — Information and resources for preventing, recognizing, and treating a heart attack. TIMI Score for UA/NSTEMI Archived 2016-11-05 at the Wayback Machine and STEMI Archived 2009-03-19 at the Wayback Machine
HEART Score for Major Cardiac Events Archived 2016-10-28 at the Wayback Machine
"Heart Attack". MedlinePlus. U.S. National Library of Medicine.
In these studies, patients had partial-onset seizures with or without secondary generalization for an average of approximately 24 years and median seizure frequency of 8.5 seizures per 28 days during an 8-week baseline period. During the trials, doses of 100, 200, and 400 milligrams (mg) daily reduced the number of seizures per 28 days compared with the placebo group. Society and culture
Legal status
The U.S. Food and Drug Administration (FDA) approved cenobamate in November 2019, and granted the application for Xcopri to SK Life Science Inc.On 28 January 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization. The applicant for this medicinal product is Arvelle Therapeutics Netherlands B.V. Ontozry was approved on 26 March 2021. References
External links
"Cenobamate". Drug Information Portal. U.S. National Library of Medicine (NLM).